Hepatită cu virusul herpetic uman 6 la doi gemeni monozigoţi imunocompetenţi – prezentare de caz

 Human herpesvirus 6 hepatitis in immunocompetent monozygotic twins – case reports

First published: 30 septembrie 2021

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/Pedi.63.3.2021.5485


Introduction. Two closely related groups of human her­pes­­virus 6 (HHV-6) are recognized, HHV-6A and HHV-6B. Although HHV-6 is considered a benign virus in im­mu­no­com­pe­tent patients, it can cause severe forms of the di­sease, such as severe hepatitis and meningoencephalitis. Case reports. We report the cases of two twin sisters with no prior medical history who presented in our hospital for fa­ti­ga­bility, jaundice, acholic stools and hyperchromic urine. The clinical examination revealed jaundice and sen­si­bi­lity in the upper right abdominal quadrant, without he­pa­to­sple­no­me­galy. Laboratory tests revealed elevated liver transaminases, elevated cholestasis enzymes and hy­per­bi­li­ru­bi­ne­mia. After excluding the usual causes of infectious hepatitis (including enteroviruses and To­xo­plas­ma infection), autoimmune hepatitis and inborn er­rors of metabolism, we tested for HHV-6 antibodies, which were positive. We confirmed the diagnosis of HHV-6 as­so­cia­ted hepatitis based on positive viremia, and the treat­ment with ursodeoxycholic acid and hepatoprotective me­di­ca­tions was started. The children had an excellent evo­lu­tion, with the resolution of symptoms in 10 days. Conclusions. HHV-6 is known for causing systemic illness in immunocompromised hosts, but some mild-to-moderate he­pa­ti­tis cases can also be found in immunocompetent patients. 

herpesvirus, HHV-6, hepatitis, immuno­competent patients


Introducere. Virusul herpetic de tip 6 (HHV-6) cuprinde două subtipuri distincte, HHV-6 A şi HHV-6 B. Chiar dacă în ma­jo­ri­ta­tea cazurilor HHV-6 determină o afectare uşoară la pa­cien­ţii imunocompetenţi, au fost descrise şi cazuri severe de he­pa­ti­tă şi meningoencefalită. Prezentare de caz. Descriem ca­zu­ri­le a două surori gemene, fără antecedente personale pa­to­lo­gi­ce, care s-au prezentat în serviciul nostru pentru fa­ti­ga­bi­li­ta­te, icter, scaune acolice şi urini hipercrome. La exa­me­nul obiectiv, s-au decelat icter şi sensibilitate la nivelul hipo­con­dru­lui drept, fără hepatosplenomegalie. Examinările pa­ra­cli­ni­ce au de­ce­lat sindrom de hepatocitoliză, sindrom de colestază şi hi­per­bi­li­ru­bi­ne­mie. Au fost excluse etiologiile in­fec­ţioa­se mai frecvente ale he­pa­titei acute (inclusiv en­te­ro­vi­ru­suri şi Toxo­plas­ma gondii), hepatita autoimună şi bolile de metabolism. Anticorpii anti-HHV-6 au fost pozitivi, iar diag­nos­ti­cul de he­pa­tită asociată infecţiei cu HHV-6 a fost con­fir­mat pe baza viremiei pozitive. Evoluţia ambelor cazuri a fost bună sub tratament cu acid ursodeoxicolic şi medicaţie hepa­to­pro­tec­toa­re, cu rezoluţia simptomelor în 10 zile. Concluzii. Deşi în mod obişnuit HHV-6 produce o afectare severă la persoane imunodeprimate, cazuri uşoare de hepatită pot fi observate şi în cazul pacienţilor imunocompetenţi.


Primary human herpesvirus 6 (HHV-6) infection is a frequent cause of acute febrile illness in small children, accounting for 20-30% of cases, mainly within the first two years of life. HHV-6 is the collective name used for two distinct viruses, HHV-6A and HHV-6B. While HHV-6A is mainly found in immunocompromised hosts, HHV-6B is a ubiquitous virus and the causative agent of a childhood disease named roseola infantum. Although it is considered a benign virus in immunocompetent patients, some cases of gastroenteritis, hepatitis and encephalitis have been described in this group(1,2).

The virus can replicate in human liver cells and may have direct cytopathic effects, as demonstrated by some in vitro studies. Hepatitis cases range from mild to severe, and in some patients it can lead to acute liver failure(2).

Case reports

We report the cases of two twin sisters who presented in our hospital for fatigability, jaundice, acholic stools and hyperchromic urine. In the first patient, the symptoms began 10 days before the admission, and her sister followed five days later. They had no prior medical history. The clinical examination of both patients revealed jaundice, more evident on the face. The weight, height, blood pressure, heart and respiratory rate were within normal range. They presented sensibility in the upper right abdominal quadrant, without hepatosplenomegaly. The intestinal transit was adequate, with acholic stools, and they presented hyperchromic urine.

The laboratory tests revealed elevated liver enzymes (alanine aminotransferase 1184 IU/L and 1272 IU/L, and aspartate aminotransferase 1198 IU/L and 980 IU/L), elevated cholestasis enzymes (gamma-glutamyl transferase 69 IU/L and 88 IU/L) and hyperbilirubinemia (total bilirubin 7.18 mg/dL and 3.41 mg/dL, and direct bilirubin 4.98 mg/dl and 2.23 mg/dl). They had no coagulation abnormalities, inflammatory syndrome and electrolyte imbalances, having a normal kidney function. We excluded the infection with hepatitis viruses A, B, C and E, herpes simplex virus 1/2, Epstein-Barr virus (EBV), cytomegalovirus (CMV), Toxoplasma gondii and alpha-1 antitrypsin deficiency. The serum amino acids, urinary organic acids and serum acylcarnitine profile were within the normal range, excluding an inborn error of metabolism. We did not detect specific antibodies for autoimmune hepatitis (antinuclear, anti-smooth muscle or anti-liver-kidney microsomal antibodies). We performed further testing for enteroviruses infections that were negative and HHV-6 antibody testing, which was positive. HHV-6 infection was confirmed in each case by the detection of HHV-6 DNA in blood samples. The liver ultrasound was within normal ranges in both patients.

Based on the clinical picture and the laboratory exa­minations, we established the diagnosis of HHV-6 associated hepatitis. As the disease severity was moderate and the liver function was normal, there was no need for antiviral therapy. We administered combined treatment with pyridoxine and aspartic acid to sustain the functionality of the liver and ursodeoxycholic acid for the cholestasis syndrome. The evolution was excellent, with the normalization of the hepatic enzymes in about one week and the resolution of jaundice in about 10 days. They were discharged afterward with the first follow-up appointment in one month.


HHV-6 is a lymphotropic virus, part of the beta-herpesvirus family, alongside Epstein-Barr virus and cytomegalovirus. It is a ubiquitous virus that uses humans as the only host. The actual incidence of HHV-6 infection is difficult to appreciate due to the lack of active screening for this virus. Primary infection usually occurs between 6 and 12 months of life and may present as asymptomatic or as an acute febrile illness accompanied by a maculopapular rash. HHV-6 infection can be less frequently responsible for a more severe presentation, including hepatitis, meningoencephalitis or macrophage activation syndrome(3-5).

In immunocompetent hosts, like our patients, the primary infection can manifest as hepatitis, associated or not with exanthem subitum. HHV-6 infections often evolve asymptomatically, especially in immunocompetent hosts, or may present with maculopapular rash (exanthem subitum) accompanied by fever, especially in HHV-6B infection.  Sometimes, HHV-6 can determine other manifestations like pneumonia, otitis, gastrointestinal symptoms, seizures, encephalitis, autoimmune conditions, Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome, myocarditis, hepatitis or acute liver failure (ALF). But it is proven that HHV-6 may cause fulminant hepatic failure and acute decompensation of chronic liver disease in children. Studies in groups of children with ALF initially of unspecified etiology have shown significantly higher viral loads of HHV-6. These severe infections are mainly determined by HHV-6A and occur with predilection in immunosuppressed hosts or with preexisting chronic liver disease(6-9). ALF secondary to HHV-6 infection is very rare (less than 1% of ALF cases) but can be extremely severe, with a mortality of over 85% in the absence of treatment. Severe HHV-6 infection associated with fulminant hepatitis is due to the direct action of the virus and secondary to massive apoptosis of the liver cells by excess production of cytokines and free radicals. The first case of ALF secondary to HHV-6 infection was described in a 3-year-old Japanese girl, in 1990. Since then, several other cases have been reported, especially in older children or teenagers, but without studies in larger patients groups. Other hepatobiliary disorders which can occur in HHV-6 infection are acute decompensation of chronic liver disease in children, giant cell hepatitis, cholestatic hepatitis or specific manifestations of mononucleosis(6-10).

HHV-6 is an important complication in patients with a liver transplantation, proving the presence of the viral DNA in hepatic graft in the areas of confluent necrosis. A study performed on a large group of patients (173 liver transplants) comes from Germany. The high level of intrahepatic HHV-6 DNA is associated with decreased graft survival. In these cases, the detection of HHV-6 IgM antibodies is not significant. According to some authors, not even HHV-6 DNA in blood samples is significant, therefore the diagnosis of HHV-6 infection in transplant recipients should be made by liver biopsy. This theory is supported by the fact that high intrahepatic levels of HHV-6 DNA (more than 11.27 copies/1000 cells) was associated with decreased graft survival after liver transplant, while low levels of intrahepatic HHV-6 DNA (latent viral infection) were not. Also, large amounts of CMV and EBV may be present in the liver, but the viral load did not correlate with the graft survival(6-9).

After an acute infection, the virus enters a latent state, with the risk of reactivation under certain circumstances, like human immunodeficiency virus infection, stem cells or solid organ transplantation. The manifestations associated with viral reactivation include cytopenia, hepatitis, pneumonitis, central nervous system involvement or graft rejection(1-3). HHV-6 hepatitis in transplant recipients is more often secondary. Approximately 40-50% of patients develop HHV-6 infection around 2 to 4 weeks after transplantation(6).

The infection’s pathophysiology consists of the penetration of the virus into the cells and the integration of the DNA into the nucleus, where the replication takes place. The next step is the acquisition of the nucleocapsid and viral envelope, and then the virions are released by exocytosis into the cell membrane. The cycle results in the death of the affected cells and the replication of the virus. After the acute infection, the virus persists in various cells, especially macrophages. Another phenomenon attributed exclusively to the herpes viruses is chromosomal integration, which consists of binding the viral genome to the cell DNA in the telomeric region of a chromosome. The infection produces a cellular immune response of the CD4+ and CD8+ T cells(3,11-13).

Liver biopsy is rarely performed during HHV-6 related hepatitis, therefore there is a small amount of data about the microscopic aspect of liver inflammation. One case report of HHV-6 hepatitis in a heart transplant recipient described mild portal inflammatory infiltrates and syncytial transformation with giant cell formation in the biliary epithelium. Another report showed no difference between hepatitis caused by HHV-6 and the one related to EBV and CMV(15). In post-liver transplantation acute hepatitis, the presence of periportal confluent necrosis was associated with high viral load HHV-6 infection and not with other viruses who presented lobular necrotico-inflammatory activity without periportal necrosis. The periportal confluent necrosis may be useful for HHV-6 diagnosis(16).

For diagnostic purposes, it is difficult to differentiate between an acute infection and a reactivation. The most frequently used are serologic studies using immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA). Still, they cannot differentiate between the HHV-6 A and HHV-6 B subtypes, as it was in the cases presented above. Other methods, like real-time polymerase chain reaction (PCR), antigen studies or viral cultures, are less often used in immunocompetent patients. Still, they can be a helpful tool in cases of infection in transplant recipients(5).

There is no consensus about the proper treatment for HHV-6 infection. In mild cases, the symptom relief treatment is enough, but in other cases, like in transplant recipients presenting with severe disease, the use of antiviral agents is accepted. Foscarnet, cidofovir and ganciclovir are the viral polymerase DNA inhibitors that have shown the inhibition of viral replication in vitro. The efficacy of the antiviral treatment initiated must be monitored by measuring the viral load using the PCR technique(3,17).


The HHV-6 is known for causing systemic illness in immunocompromised hosts, but some mild-to-moderate hepatitis cases can be found in im­mu­no­competent persons. The severity of cases is he­te­ro­geneous due to the association with other infections and illnesses, but it must be considered in cases of hepatitis of unknown cause.  


Conflicts of interests: The authors declare no con­flict of interests.


  1. Caserta MT, Mock DJ, Dewhurts S. Human herpesvirus 6. Clin Infect Dis. 2001;33(6):829-33.

  2. Maiju H, Krister H, Irmeli L. Human Herpesvirus-6, and acute liver failure. Transplantation. 2003; 76:536-539.

  3. Agut H, Bonnafous J, Gautheret-Dejean A. Update on infections with human herpesviruses 6A, 6B and 7. Med Mal Infect. 2017;47(2):83-91.

  4. Razonable RR, Lautenschlager I. Impact of human herpes virus 6 in liver transplantation. World J Hepatol. 2010;2(9):345-53. 

  5. Massih RCA, Razonable RR. Human herpesvirus 6 infections after liver transplantation. World J Gastroenterol. 2009;15(21):2561-69.

  6. Yoshikawa T. Human Herpes Virus 6 Causes Hepatitis in Transplant Recipients. Intern Med. 2006;45(7):417-8.

  7. Kuntzen T, Friedrichs N, Fischer HP, Eis-Hübinger AM, Sauerbruch T, Spengler U. Postinfantile giant cell hepatitis with autoimmune features following a human herpesvirus 6-induced adverse drug reaction. Eur J Gastroenterol Hepatol. 2005;17(10):1131-4. 

  8. Al-Abdwani RM, Khamis FA, Balkhair A, Sacharia M, Wali YA. A child with human parvovirus B19 infection induced aplastic anemia and acute hepatitis: effectiveness of immunosuppressive therapy. Pediatr Hematol Oncol. 2008;25(7):699-703. 

  9. Cacheux W, Carbonell N, Rosmorduc O, et al. HHV-6-related acute liver failure in two immunocompetent adults: favorable outcome after liver transplantation and/or ganciclovir therapy. J Intern Med. 2005;258(6):573-8.

  10. Grama A, Burac L, Cainap S, et al. Acute liver failure in children: aetiology and evolution. Archives of Disease in Childhood. 2019;6:104

  11. Tajiri H, Tanaka-Taya K, Ozaki Y, et al. Chronic hepatitis in an infant, in association with human herpesvirus-6 infection. J Pediatr. 1997;131:473-475. 

  12. Kiyoshi A, Jin Y, Irie H, et al. Are there histopathologic characteristics particular to fulminant hepatic failure caused by human herpesvirus-6 infection? A case report and discussion. Human Pathology. 2001;32(8):887-89. 

  13. Endo A, Watanabe K, Ohye T, et al. Molecular and virological evidence of viral activation from chromosomally integrated human herpesvirus 6A in a patient with X-linked severe combined immunodeficiency. Clin Infect Dis. 2014;59:545-48. 

  14. Randhawa PS, Jenkins FJ, Nalesnik MA, et al. Herpesvirus 6 variant A infection after heart transplantation with giant cell transformation in bile ductular and gastroduodenal epithelium. Am J Surg Pathol. 1997;21:847-53. 

  15. Imoto S, Kim SR, Inagi R, et al. A case of HHV-6 mononucleosis occurred as acute hepatitis with special reference to the identification of virus infected cells in liver biopsy specimen using non-isotopic ISH procedure. Kanzo. 2000;41:104-108.

  16. Buyse S, Roque-Afonso AM, Vaghefi P, et al. Acute hepatitis with periportal confluent necrosis associated with human herpesvirus 6 infection in liver transplant patients. Am J Clin Pathol. 2013;140(3):403-9.

  17. Agout H, Bonnafous P, Gautheret-Dejean A. Laboratory, and clinical aspects of human herpesvirus infections. Clin Microbiol Rev. 2015;28:313-335.  

Articole din ediţiile anterioare

UP-TO-DATE | Ediţia 2 58 / 2020

Medicamentele şi toxicitatea hepatică la copil

Alina Grama, Claudia Sîrbe, Tudor Lucian Pop

Toxicitatea secundară ingestiei de medicamente reprezintă o problemă în întreaga lume, fiind o cauză importantă de mor­bi­di­tate şi mortalitate la...

23 mai 2020
GHID | Ediţia 3 47 / 2017

Transmiterea hepatitelor B și C de la mamă la copil - o problemă actuală

Prof. dr. Evelina Moraru, Dan Cristian Moraru, Bogdan A. Stana

Hepatitele cronice la copil sunt încă în actualitate, prin evoluția particulară și dificultățile de tra­ta­ment. Transmiterea verticală rămâne o mo...

03 noiembrie 2017
CLINICAL STUDIES | Ediţia 3 67 / 2022

Tratament şi prognostic în hepatita autoimună la copil

Claudia Sîrbe, Alina Grama, Ancuţa Cutaş, Gabriel Benţa, Mara Puiu, Diana-Alexandra Borcău, Bianca Mariş, Simona Rednic, Tudor Lucian Pop

Introducere. Hepatita autoimună (HAI) este una dintre afec­ţiu­nile hepatice autoimune recunoscute în populaţia pe­dia­trică, ală­turi de colangita...

31 octombrie 2022

Hepatita toxică la copil - consideraţii pe baza unui caz clinic de intoxicaţie acută cu etanol

Bogdan A. Stana, Prof. dr. Evelina Moraru, Cristina Jităreanu

Toxic hepatitis in children - considerations upon a case of acute ethanol intoxication

06 ianuarie 2016